<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04100603</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-004</org_study_id>
    <nct_id>NCT04100603</nct_id>
  </id_info>
  <brief_title>A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection</brief_title>
  <official_title>A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to correlate microbiome sequencing data with information provided by&#xD;
      patients and their medical records.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this Research Study is to better understand how the genetic information in&#xD;
      subject's microbiome correlates to infection with C. diff.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing</measure>
    <time_frame>1 year</time_frame>
    <description>Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized with C. diff infection</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Clostridium Difficile</condition>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Microbiome</condition>
  <condition>CDI</condition>
  <arm_group>
    <arm_group_label>Patients with CDI</arm_group_label>
    <description>Patients who are infected with C. diff</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>There is no intervention for this study</description>
    <arm_group_label>Patients with CDI</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with C. difficile infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willingness to sign informed consent&#xD;
&#xD;
          -  Diagnosis of C. difficile infection&#xD;
&#xD;
          -  Age of 18 and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal by patient to sign informed consent form&#xD;
&#xD;
          -  Treatment with antibiotics 2 weeks prior to screening&#xD;
&#xD;
          -  Treatment with probiotics 6 weeks prior to screening&#xD;
&#xD;
          -  History of bariatric surgery, total colectomy with ileorectal anastomosis or&#xD;
             proctocolectomy.&#xD;
&#xD;
          -  Postoperative stoma, ostomy, or ileoanal pouch&#xD;
&#xD;
          -  Participation in any experimental drug protocol within the past 12 weeks&#xD;
&#xD;
          -  Treatment with total parenteral nutrition&#xD;
&#xD;
          -  Any clinically significant evidence of disease that could interfere with the subject's&#xD;
             ability to enter the trial&#xD;
&#xD;
          -  Inability of patient to adequately communicate with the investigator or their&#xD;
             respective designee and/or comply with the requirements of the entire study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>18053390549</phone>
    <email>drsabinehazan@progenabiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels</last_name>
    <phone>18053390549</phone>
    <email>jordan@progenabiome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-339-0549</phone>
      <email>drsabinehazan@progenabiome.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Daniels, MS</last_name>
      <phone>18053390549</phone>
      <email>jordan@progenabiome.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only aggregated deidentified data will be made available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

